Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 80 years of age
- People who have signed a consent form showing they understand the study's purpose and are willing to take part, including allowing their MRI scans and tissue samples to be used for genetic and other analyses, and agreeing to attend regular follow-up appointments
- People who had an MRI scan before prostate removal surgery, including specific scan types (T2-weighted, diffusion-weighted, and contrast-enhanced images) meeting standard radiology guidelines — this is not required for those with cancer that has spread to other parts of the body (metastatic cohort)
- People who have a preserved tissue sample (from prostate removal surgery) available for genetic and other analyses — for those with metastatic cancer, a biopsy sample from the prostate or another affected site is acceptable
- People with a confirmed diagnosis of prostate adenocarcinoma (a specific type of prostate cancer)
- People who had a PSA blood test and a physical prostate examination within 3 months before surgery — this does not apply to those in the metastatic group
- People who had at least one PSA blood test taken between 3 and 8 weeks after surgery — this does not apply to those in the metastatic group
- People who have been followed up for at least 2 years after surgery (or after diagnosis for those with metastatic cancer), or until death
Who may not be able to join:
- People who have had both testicles surgically removed
- People who received hormone therapy or any other prostate cancer treatment before their prostate removal surgery
- People who had radiation therapy to the pelvic area before prostate removal surgery
- People who have had another active cancer in the past 24 months, with the exception of prostate cancer, certain non-invasive bladder cancers, cured skin cancers (not including melanoma), or other cancers considered very unlikely to return
- People who were on an active surveillance program for more than 12 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Carlotta Palumbo, MD, University of Piemonte Orientale
Phone: +393491289501
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
integration of pathologic, imaging, genomic and transcriptomic profiles of prostate cancer; Validation of the artificial intelligence-based platform generated in the previous phase
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.